AVRYGEN CORPORATION — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Glioblastoma Multiforme is a lethal cancer with devas
AVRYGEN CORPORATION — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,980
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PAR10-286
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): Glioblastoma Multiforme is a lethal cancer with devastating prognosis. Glioblastoma affects 5-8 persons per 100,000 population. Even using the most aggressive therapeutic approaches, which include, surgical resection oftumor mass, radiation therapy and chemo intervention, median survival term is less than 15-months. The high recurrence of this cancer is due to remnant reservoir of stem cells (Glioma Stem Cells: GSC) that renew the tumor after resection. Therefore, thereis urgent unmet need to develop novel targeted therapeutics for Glioblastoma that target critical molecular mediators in its reservoir of stem like cells. Results of our preliminary studies drive this proposal. In preliminar studies, we have formulated novel stabilized and targeted nanoparticles for delivery of dual disease specific siRNAs to Glioblastoma stem like cells. Our nanoparticles carry specific targeting moieties that can readily cross the blood brain barrier and home-in to Glioblastoma cell